Text Size

Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II

This study has been completed.
Sponsor:
Collaborators:
Eli Lilly and Company
Regional Mental Health Care, London
Information provided by:
Lawson Health Research Institute
ClinicalTrials.gov Identifier:
NCT00377117
First received: September 14, 2006
Last updated: July 20, 2007
Last verified: July 2007
History of Changes
  Purpose

The purpose of this study is to learn more about the relationship between serious mental illness and the detection and management of diabetes and pre-diabetic conditions. Patients who have been diagnosed with schizophrenia are at an increased risk for developing diabetes and pre-diabetic conditions such as impaired glucose tolerance and impaired fasting glucose. In addition, novel antipsychotics have also been linked to impaired glucose metabolism and increased incidence of diabetes. The medical management of these patients may be difficult ot achieve through standard family practice. The objectives of this project are to: screen a sample of this high-risk population using an Oral Glucose Tolerance Test (OGTT), and to provide multidisciplinary team support to those identified as having diabetes or a pre-diabetic condition.


Condition Intervention Phase
Diabetes Mellitus
Schizophrenia
Psychotic Disorders
 Procedure: Management
Procedure: Screening
 Phase 1
Phase 2

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Retrospective/Prospective
Official Title: Diabetes Screening, Risk Management, and Disease Management in a High-Risk Mental Health Population.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Lawson Health Research Institute:

Enrollment: 39
Study Start Date: May 2006
Study Completion Date: July 2007
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients active in current Regional Mental Health Care London, Specialized Adult London Ambulatory Care and Assertive Community Treatment programs with known diagnosis of a Psychotic Disorder and/or use of Novel Antipsychotics.
  • Must have family physician contact and ability to consent to medical care.

Exclusion Criteria:

  • Any patient with declaration on file stating incapable of consenting to medical treatment.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00377117

Locations
Canada, Ontario
Regional Mental Health Care London
London, Ontario, Canada, N6A 4H1
Sponsors and Collaborators
Lawson Health Research Institute
Eli Lilly and Company
Regional Mental Health Care, London
Investigators
Principal Investigator: Stewart B Harris, MD MPH CCFP FACPM Centre for Studies in Family Medicine
Principal Investigator: David RS Haslam, MSc MD FRCPC Regional Mental Health Care, London
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00377117     History of Changes
Other Study ID Numbers: R-05-470
Study First Received: September 14, 2006
Last Updated: July 20, 2007
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Diabetes Mellitus
Psychotic Disorders
Mental Disorders
Schizophrenia
 Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on June 17, 2013